Literature DB >> 20847825

Targeted Therapy in Breast Cancer.

Andreas Schneeweiss1.   

Abstract

Entities:  

Year:  2010        PMID： 20847825      PMCID： PMC2931050          DOI： 10.1159/000315676

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  17 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Targeted Therapy for Early and Locally Advanced Breast Cancer.

Authors:  Michael Untch
Journal:  Breast Care (Basel)       Date:  2010-06-16       Impact factor: 2.860

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

6.  Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

Authors:  Alvaro Moreno-Aspitia; Roscoe F Morton; David W Hillman; Wilma L Lingle; Kendrith M Rowland; Martin Wiesenfeld; Patrick J Flynn; Tom R Fitch; Edith A Perez
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.

Authors:  Alfredo Santinelli; Eleonora Pisa; Daniela Stramazzotti; Guidalberto Fabris
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

Review 8.  Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

Authors:  Nicholas Wilcken; Rachel Dear
Journal:  Eur J Cancer       Date:  2008-08-20       Impact factor: 9.162

9.  Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.

Authors:  Elisabetta Munzone; Giuseppe Curigliano; Andrea Rocca; Giuseppina Bonizzi; Giuseppe Renne; Aron Goldhirsch; Franco Nolè
Journal:  Breast Cancer Res       Date:  2005-12-07       Impact factor: 6.466

10.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

Authors:  Pratyaksha Wirapati; Christos Sotiriou; Susanne Kunkel; Pierre Farmer; Sylvain Pradervand; Benjamin Haibe-Kains; Christine Desmedt; Michail Ignatiadis; Thierry Sengstag; Frédéric Schütz; Darlene R Goldstein; Martine Piccart; Mauro Delorenzi
Journal:  Breast Cancer Res       Date:  2008-07-28       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.